Patents by Inventor Younggyu Kong
Younggyu Kong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10889574Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: GrantFiled: August 30, 2019Date of Patent: January 12, 2021Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
-
Patent number: 10640496Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: GrantFiled: June 15, 2017Date of Patent: May 5, 2020Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
-
Publication number: 20190382390Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: ApplicationFiled: August 30, 2019Publication date: December 19, 2019Applicants: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon YOON, Se-Hwan PARK, Ji-sung YOON, Soongyu CHOI, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Kwang-Seop SONG, Min Ju KIM, So Ok PARK
-
Publication number: 20190169174Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: ApplicationFiled: June 15, 2017Publication date: June 6, 2019Applicants: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon YOON, Se-Hwan PARK, Ji-Sung YOON, Soongyu CHOI, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Kwang-Seop SONG, Min Ju KIM, So Ok PARK
-
Pyrazole derivatives as TNIK, IKK? and TBK1 inhibitor and pharmaceutical composition comprising same
Patent number: 10294207Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: March 29, 2016Date of Patent: May 21, 2019Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kisoo Park, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Kwang-Seop Song, Min Ju Kim, So Ok Park, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong -
Patent number: 10239873Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: March 24, 2016Date of Patent: March 26, 2019Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang-Seop Song, Hee Jeong Seo, Sang-ho Ma, Eun-Jung Park, Younggyu Kong, So Ok Park, Kisoo Park, Ickhwan Son, Min Ju Kim, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong
-
Patent number: 9856216Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: April 21, 2016Date of Patent: January 2, 2018Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Eun-Jung Park, Hee Jeong Seo, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Man-Young Cha, Mi-Soon Kim, Kisoo Park
-
Publication number: 20160311772Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: ApplicationFiled: April 21, 2016Publication date: October 27, 2016Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Eun-Jung PARK, Hee Jeong SEO, Younggyu KONG, Ickhwan SON, Sang-ho MA, Man-Young CHA, Mi-Soon KIM, Kisoo PARK
-
Publication number: 20160297815Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: ApplicationFiled: March 24, 2016Publication date: October 13, 2016Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Kwang-Seop SONG, Hee Jeong SEO, Sang-ho MA, Eun-Jung PARK, Younggyu KONG, So Ok PARK, Kisoo PARK, Ickhwan SON, Min Ju KIM, Man-Young CHA, Mi-Soon KIM, Sang Mi KANG, Dong Hyuk JANG, Jangwon HONG
-
PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Publication number: 20160289196Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: ApplicationFiled: March 29, 2016Publication date: October 6, 2016Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Kisoo PARK, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Ickhwan SON, Sang-ho MA, Kwang-Seop SONG, Min Ju KIM, So Ok PARK, Man-Young CHA, Mi-Soon KIM, Sang Mi KANG, Dong Hyuk JANG, Jangwon HONG -
Patent number: 9371303Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.Type: GrantFiled: January 9, 2015Date of Patent: June 21, 2016Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang-Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
-
Patent number: 9340521Abstract: The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.Type: GrantFiled: March 18, 2013Date of Patent: May 17, 2016Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Jae Eun Kim, Kwang-Seop Song, Suk Ho Lee, Kisoo Park, Hee Jeong Seo, Min Ju Kim, Eun-Jung Park, So Ok Park, Younggyu Kong, Hyunku Kang, Ickhwan Son, Myung Eun Jung, Man-Young Cha, Hyun Jung Kim, Jun Sung Lee, Mi-Soon Kim, Min Woo Lee, Kinam Lee
-
Publication number: 20150152075Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.Type: ApplicationFiled: January 9, 2015Publication date: June 4, 2015Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Kwang-Seop SONG, Suk Ho LEE, Min Ju KIM, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, So Ok PARK, Hyunku KANG, Myung Eun JUNG, Kinam LEE, Hyun Jung KIM, Jun Sung LEE, Min Woo LEE, Mi-Soon KIM, Dong Ho HONG, Misuk KANG
-
Patent number: 9034921Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.Type: GrantFiled: June 1, 2012Date of Patent: May 19, 2015Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang
-
Publication number: 20140274918Abstract: The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.Type: ApplicationFiled: March 18, 2013Publication date: September 18, 2014Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Jae Eun KIM, Kwang-Seop SONG, Suk Ho LEE, Kisoo PARK, Hee Jeong SEO, Min Ju KIM, Eun-Jung PARK, So Ok PARK, Younggyu KONG, Hyunku KANG, Ickhawn SON, Myung Eun JUNG, Man-Young CHA, Hyun Jung KIM, Jun Sung LEE, Mi-Soon KIM, Min Woo LEE, Kinam LEE
-
Patent number: 8785453Abstract: A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.Type: GrantFiled: November 5, 2010Date of Patent: July 22, 2014Assignee: Green Cross CorporationInventors: Jinhwa Lee, Eun-Jung Park, Suk Youn Kang, Younggyu Kong, Junwon Lee, Hyun Jung Kim, Myung Eun Jung, Ki-Nam Lee, Jeongmin Kim, Ae Nim Pae, Woo-Kyu Park
-
Publication number: 20140088079Abstract: The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.Type: ApplicationFiled: June 1, 2012Publication date: March 27, 2014Applicant: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon KIM, Dong Ho Hong, Misuk Kang
-
Patent number: 8586550Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.Type: GrantFiled: June 10, 2011Date of Patent: November 19, 2013Assignee: Green Cross CorporationInventors: Jinhwa Lee, Jeongmin Kim, Suk Ho Lee, Junwon Lee, Kwang-Seop Song, Eun-Jung Park, Min Ju Kim, Hee Jeong Seo, Sung-Han Lee, Eun Jung Son, Jong Yup Kim, Suk Youn Kang, Younggyu Kong
-
Publication number: 20130090298Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.Type: ApplicationFiled: June 10, 2011Publication date: April 11, 2013Applicant: GREEN CROSS CORPORATIONInventors: Jinhwa Lee, Jeongmin Kim, Suk Ho Lee, Junwon Lee, Kwang-Seop Song, Eun-Jung Park, Min Ju Kim, Hee Jeong Seo, Sung-Han Lee, Eun Jung Son, Jong Yup Kim, Suk Youn Kang, Younggyu Kong
-
Publication number: 20120232090Abstract: A novel arylpiperazine-containing purine derivatives and a pharmaceutical composition comprising the same as an active ingredient, which are useful for preventing or treating depressive disorders, are provided.Type: ApplicationFiled: November 5, 2010Publication date: September 13, 2012Applicant: GREEN CROSS CORPORATIONInventors: Jinhwa Lee, Eun-Jung Park, Suk Youn Kang, Younggyu Kong, Junwon Lee, Hyun Jung Kim, Myung Eun Jung, Ki-Nam Lee, Jeongmin Kim, Ae Nim Pae, Woo-Kyu Park